Our Mastery
Testimonial
- "Amazing success ratio in such uncertain market and paid service is very affordable ...Good job done by your team...keep it up guys."
-Venkat (Chennai)
Party Plot Owner - "I am trading in stock market since last 8 years; I have subscribed services from many advisory companies. Conclusion is that no one can provide 100% accuracy in this NSE market. But accuracy of intraday tips from this firm is the highest among all share tips companies" Rahul Varma (Mumbai)
Owner of an Insurance Firm - "I have taken free trial of intraday tips for 2 days and 80% call is profitable. Then I have subscribed paid membership for trading advice and now I am quite satisfied with services. Important thing is do not think more; Just trade what you are suggested" -Kevin Patel (Ahmedabad)
BDM at IT Company - "Made Good Profit in the Intraday, Jackpot Calls, F&o Tips. Overall Service is very good. Especially I like your Fast tips Sms Service & Exit Call System. Your tips have very good performance." -Manoj Arora (Delhi)
CEO of Real Estate Company
Cipla Ltd share price today (on 28 May 2023).
We Provide Best stock tips for Cipla Ltd. A1 Intraday Tips is accurate share tips Provider Company in India in Nse market. A1 Intraday Tips, also provide Daily Charts with Nse Share Market current price of Cipla Ltd with today performance in nse market. Contact Us for Jackpot Stock tips.
Get Free Stock Tips for Cipla Ltd
BSE: 500087 | NSE: CIPLA | ISIN: INE059A01026 Market Cap: [Rs.Cr.] 30,093 | Face Value: [Rs.] 2 Industry: Pharmaceuticals - Indian - Bulk Drugs & Formln
Cipla was established in 1935 by setting up the Chemical, Industrial & Pharmaceutical Laboratories. From the time Cipla came to the aid of the nation gasping for essential medicines during the Second World War, Cipla has been among the leaders in the pharmaceutical industry in India.
Cipla Ltd is a pharmaceutical company. The company focuses on development of new formulations and has a wide range of pharmaceutical products. It offers prescription drugs, bulk drugs, animal products and pesticides. It also offers a wide range of food and beverages, baked foods, oral hygiene products, detergents, room fresheners and personal care products. Cipla Ltd was incorporated in the year 1935 with the name Chemical, Industrial & Pharmaceutical Laboratories Ltd. Khwaja Abdul Hamied, the founder of Cipla gave the company all his patent and proprietary formulas for several drugs and medicines, without charging any royalty. On August 17, 1935, Cipla was registered as a public limited company with an authorized capital of Rs. 6 lakh. In the year 1941, as the Second World War cuts off drug supplies, the company starts producing fine chemicals, dedicating all its facilities for the war effort. In the year 1952, the company set up first research division for attaining self-sufficiency in technological development. In the year 1960, they started operations at second plant at Vikhroli, Mumbai, producing fine chemicals with special emphasis on natural products. In the year 1968, the company manufactured ampicillin for the first time in the country.
In the year 1972, the company started Agricultural Research Division at Bangalore, for scientific cultivation of medicinal plants. In the year 1976, they launched medicinal aerosols for asthma. In the year 1980, the company won Chemexcil Award for Excellence for exports. In the year 1982, the company started operations in their fourth factory at Patalganga, Maharashtra. In the year 1984, they developed anti-cancer drugs, vinblastine and vincristine in collaboration with the National Chemical Laboratory, Pune. Also, they won Sir P C Ray Award for developing in-house technology for indigenous manufacture of a number of basic drugs. In the year 1985, US FDA approved the company's bulk drug manufacturing facilities. In the year 1988, they won National Award for Successful Commercialisation of Publicly Funded R&D. In the year 1991, the company launched etoposide, a breakthrough in cancer chemotherapy, in association with Indian Institute of Chemical Technology. Also, they manufactured antiretroviral drug, zidovudine, in technological collaboration with Indian Institute of Chemical Technology, Hyderabad. In the year 1994, the company commenced commercial operations in their fifth factory at Kurkumbh, Maharashtra. In the year 1997, they launched transparent Rotahaler, the world's first such dry powder inhaler device.
In the year 1998, they launched lamivudine. The company becomes one of the few companies in the world to offer all three component drugs of retroviral combination therapy. In the year 1999, the company launched Nevirapine, antiretroviral drug, used to prevent the transmission of AIDS from mother to child. In the year 2000, the company became the first company, outside the USA and Europe to launch CFC-free inhalers - ten years before the deadline to phase out use of CFC in medicinal products. In the year 2002, the company set up four state-of-the-art manufacturing facilities in Goa. In the year 2003, they launched TIOVA (Tiotropium bromide), a novel inhaled, long-acting anticholinergic bronchodilator that is employed as a once-daily maintenance treatment for patients with chronic obstructive pulmonary disease (COPD). Also, they commissioned second phase of manufacturing operations at Goa. In the year 2005, the company set up state-of-the-art facility for manufacture of formulations at Baddi, Himachal Pradesh. In the year 2007, they set up state-of-the-art facility for manufacture of formulations at Sikkim. In February 2007, the company entered into a development and supply agreement with Drugs for Neglected Diseases Initiative (DNDi), a global non-profit organization, for a new anti-malarial combination drug as a global initiative.
During the year 2009-10, the company sold their intellectual property rights and technical know-how of 'i-pill', an emergency contraceptive brand, to Piramal Healthcare Ltd, for the territory of India, at an aggregate consideration of Rs. 95 crore. Also, they entered into a strategic alliance with Stempeutics Research Pvt. Ltd., promoted by the Manipal Group, for the marketing rights of stem-cell-based products being developed by Stempeutics. Cipla is sponsoring up to Rs. 50 crore, in the initial phase, for research and development of these products. In April 2010, the company commenced commercial production of pharmaceutical formulations at the Special Economic Zone (SEZ) project, at Indore, Madhya Pradesh.This project includes facilities for the manufacture of aerosols, respules, liquid orals, pre-filled syringes (PFS), nasal sprays, large volume parenterals (LVP), eye drops, tablets and capsules. The total investment for this project is about Rs. 900 crore. In May 2010, the company acquired an undertaking for Rs. 30.64 crore, by way of a slump sale arrangement. The undertaking has a manufacturing facility, approved by US FDA and WHO, for APIs and intermediates. It is located at Kurkumbh (Pune district). Also, the company set up a wholly-owned subsidiary, 'Cipla Singapore Pte Ltd', in Singapore to aid logistics and distribution of the company's export business.
In May 2010, the company acquired 100% shareholding of a company for Rs. 51.38 crore. This company has a state-of-the-art formulations manufacturing facility at Sikkim with capabilities to manufacture tablets, capsules, oral liquids, injections, dry syrup and ointments/creams. During the year 2010-11, the company introduced a number of new drugs and formulations, such as Entavir (entecavir tablets), an antiviral for hepatitis B; Febucip (febuxostat tablets), a drug for gout; Flosoft (fluorometholone acetate ophthalmic suspension), a topical steroid for eye inflammation; Foracort (formoterol and budesonide autohaler), an asthma controller therapy in a new easy-to-use breath actuated inhaler; Furamist AZ (fluticasone furoate and azelastine hydrochloride nasal spray), a nasal spray for allergic rhinitis, and Montair FX (montelukast and fexofenadine tablets), an antiallergic combination for rhinitis.
During the year, Cipla (Mauritius) Ltd, Cipla (UK) Ltd, Cipla-Oz Pty Ltd, Four M Propack Pvt Ltd, Goldencross Pharma Pvt Ltd, Medispray Laboratories Pvt Ltd, Meditab Holdings Ltd, Meditab Pharmaceuticals South Africa (Pty) Ltd, Meditab Specialities New Zealand Ltd, Meditab Specialities Pvt Ltd, Sitec Labs Pvt Ltd and STD Chemicals Ltd. The company is setting up API facilities at Bengaluru and Kurkumbh. They are also upgrading the API facilities at Patalganga. The total investment for these projects is about Rs. 400 crore. The company proposes to subscribe to the share capital of two biotechnology companies, located in India and Hong Kong, to obtain a 40 per cent and a 25 per cent share, respectively. The total investment will be about USD 65 million, in a phased manner, for setting up state-of-the-art facilities for biosimilar products in Goa and China.
According to the Consolidated - Audited financial statement for the Year of 2012, total net operating revenues increased with 11.41%, from INR 6,426.65 tens of millions to INR 7,160.23 tens of millions. Operating result increased from INR 1,339.75 tens of millions to INR 1,658.85 tens of millions which means 23.82% change. The results of the period increased 17.99% reaching INR 1,141.3 tens of millions at the end of the period against INR 967.27 tens of millions last year. Return on equity (Net income/Total equity) went from 14.51% to 14.94%, the Return On Asset (Net income / Total Asset) went from 12.98% to 12.21% and the Net Profit Margin (Net Income/Net Sales) went from 15.05% to 15.94% when compared to the same period of last year. The Debt to Equity Ratio (Total Liabilities/Equity) was 122.40% compared to 111.78% of last year. Finally, the Current Ratio (Current Assets/Current Liabilities) went from 3.95 to 3.03 when compared to the previous year.
( Equity cash, Nse fno, jackpot call, sure shot call, btst/stbt call )
Under one plan with lowest price
for free trial visit Stock tips for day Traders
Nse Listed Companies with Live Charts
with live charts starting with that Alphabet.)
| A | B | C | D | E | F | G | H | I | J |
| K | L | M | N | O | P | Q | R | S | T |
| U | V | W | X | Y | Z |
